









市場行情
/
股票
/
nasdaq-spry
/

ARS Pharmaceuticals Inc

SPRY

13.060USD

+2.110+19.27%

收盤 01/09, 16:00（美東）報價延遲15分鐘

1.29B總市值

虧損本益比TTM



ARS Pharmaceuticals Inc

13.060

+2.110+19.27%

概覽公司財務分析

概覽

公司

財務

分析

關於 ARS Pharmaceuticals Inc 公司

ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the commercialization and development of neffy for the needle-free intranasal delivery of epinephrine for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an innovative absorption enhancer called Intravail, which allows neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.

ARS Pharmaceuticals Inc簡介



公司代碼SPRY

公司名稱ARS Pharmaceuticals Inc

上市日期Dec 04, 2020

CEOLowenthal (Richard E)

員工數量155

證券類型Ordinary Share

年結日Dec 04

公司地址11682 El Camino Real, Suite 300

城市SAN DIEGO

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編92130

電話18587719307

網址https://ars-pharma.com/

公司代碼SPRY

上市日期Dec 04, 2020

CEOLowenthal (Richard E)

ARS Pharmaceuticals Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Mr. Richard E. Lowenthal

President, Chief Executive Officer, Director

6.83M

-1143342.00%

Dr. Sarina Tanimoto, M.D.

Chief Medical Officer

4.57M

-556658.00%

Mr. Alexander A. Fitzpatrick, Esq., J.D.

Secretary and Chief Legal Officer

86.26K

-2969.00%

Mr. Michael Kelly

Independent Director

83.22K

Mr. Brian T. Dorsey

Chief Operating Officer

7.65K

Dr. Laura K. Shawver, Ph.D.

Director

Dr. Peter A. Thompson, M.D.

Independent Director

Mr. Saqib Islam, J.D.

Independent Director

Ms. Kathleen D. (Kathy) Scott

Chief Financial Officer

Mr. Eric Karas

Chief Commercial Officer

名稱

名稱/職務

職務

持股

持股變動

Mr. Richard E. Lowenthal

President, Chief Executive Officer, Director

6.83M

-1143342.00%

Dr. Sarina Tanimoto, M.D.

Chief Medical Officer

4.57M

-556658.00%

Mr. Alexander A. Fitzpatrick, Esq., J.D.

Secretary and Chief Legal Officer

86.26K

-2969.00%

Mr. Michael Kelly

Independent Director

83.22K

Mr. Brian T. Dorsey

Chief Operating Officer

7.65K

Dr. Laura K. Shawver, Ph.D.

Director

收入明細

由於公司未披露，未能獲取相關數據

由於公司未披露，未能獲取相關數據

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 1月10日週六

持股股東

股東類型

持股股東

佔比

RA Capital Management, LP

10.99%

OrbiMed Advisors, LLC

8.39%

Deerfield Management Company, L.P.

7.59%

Lowenthal (Richard E)

6.91%

Pratik Shah Living Trust

4.88%

其他

61.25%

持股股東

佔比

RA Capital Management, LP

10.99%

OrbiMed Advisors, LLC

8.39%

Deerfield Management Company, L.P.

7.59%

Lowenthal (Richard E)

6.91%

Pratik Shah Living Trust

4.88%

其他

61.25%

股東類型

持股股東

佔比

Hedge Fund

22.26%

Investment Advisor/Hedge Fund

19.59%

Investment Advisor

16.53%

Venture Capital

15.19%

Individual Investor

11.94%

Private Equity

8.39%

Corporation

4.88%

Research Firm

3.80%

Insurance Company

0.59%

機構持股



更新時間: 1月1日週四

報告期間

機構數

持股數

持股佔比

持股變動

2025Q4

392

85.62M

86.61%

-10.63M

2025Q3

381

87.74M

88.78%

-2.41M

2025Q2

367

96.00M

97.76%

-11.66M

2025Q1

380

100.63M

102.48%

-12.75M

2024Q4

345

96.62M

99.42%

-14.07M

2024Q3

320

88.19M

90.90%

-18.52M

2024Q2

291

87.17M

89.94%

-20.35M

2024Q1

289

89.45M

92.60%

-16.44M

2023Q4

280

92.18M

96.08%

-6.49M

2023Q3

283

95.82M

104.35%

+1.21M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

RA Capital Management, LP

10.86M

10.99%

Sep 30, 2025

OrbiMed Advisors, LLC

8.29M

8.39%

Sep 30, 2025

Deerfield Management Company, L.P.

7.50M

7.59%

-106.41K

-1.40%

Sep 30, 2025

Lowenthal (Richard E)

6.83M

6.91%

-1.14M

-14.34%

Mar 31, 2025

Pratik Shah Living Trust

4.82M

4.88%

Mar 31, 2025

Tanimoto (Sarina)

4.57M

4.63%

-556.66K

-10.85%

Mar 31, 2025

Rubric Capital Management LP

4.50M

4.55%

+3.21M

+247.52%

Sep 30, 2025

BlackRock Institutional Trust Company, N.A.

4.35M

4.4%

+419.68K

+10.68%

Sep 30, 2025

SR One Capital Management, LP

4.01M

4.06%

Sep 30, 2025

The Vanguard Group, Inc.

3.49M

3.53%

+237.63K

+7.31%

Sep 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

ALPS Medical Breakthroughs ETF

0.38%

State Street SPDR S&P Biotech ETF

0.32%

Direxion Daily S&P Biotech Bull 3X Shares

0.16%

VictoryShares US Small Mid Cap Value Momentum ETF

0.16%

ProShares Ultra Nasdaq Biotechnology

0.11%

Principal U.S. Small-Cap ETF

0.09%

Invesco Nasdaq Biotechnology ETF

0.08%

iShares US Small-Cap Equity Factor ETF

0.05%

iShares Biotechnology ETF

0.05%

iShares MSCI USA Small-Cap Min Vol Factor ETF

0.04%

ALPS Medical Breakthroughs ETF

佔比0.38%

State Street SPDR S&P Biotech ETF

佔比0.32%

Direxion Daily S&P Biotech Bull 3X Shares

佔比0.16%

VictoryShares US Small Mid Cap Value Momentum ETF

佔比0.16%

ProShares Ultra Nasdaq Biotechnology

佔比0.11%

Principal U.S. Small-Cap ETF

佔比0.09%

Invesco Nasdaq Biotechnology ETF

佔比0.08%

iShares US Small-Cap Equity Factor ETF

佔比0.05%

iShares Biotechnology ETF

佔比0.05%

iShares MSCI USA Small-Cap Min Vol Factor ETF

佔比0.04%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

ARS Pharmaceuticals Inc的前五大股東是誰？



ARS Pharmaceuticals Inc的前五大股東如下：
RA Capital Management, LP
持有股份：10.86M
佔總股份比例：10.99%。
OrbiMed Advisors, LLC
持有股份：8.29M
佔總股份比例：8.39%。
Deerfield Management Company, L.P.
持有股份：7.50M
佔總股份比例：7.59%。
Lowenthal (Richard E)
持有股份：6.83M
佔總股份比例：6.91%。
Pratik Shah Living Trust
持有股份：4.82M
佔總股份比例：4.88%。